MedTrace Logo

SB208 for the Treatment of Tinea Pedis

NCT02860052 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 222

Last updated 2019-01-10

No results posted yet for this study

Summary

This is a phase 2, multi-center, double-blind, randomized, vehicle-controlled study to be conducted in non immunocompromised adult subjects with interdigital tinea pedis.

Conditions

  • Tinea Pedis

Interventions

DRUG

SB208 2%

Apply once daily to one or both feet for 14 days

DRUG

SB208 4%

Apply once daily to one or both feet for 14 days

DRUG

SB208 16%

Apply once daily to one or both feet for 14 days

DRUG

Vehicle Gel

Apply once daily to one or both feet for 14 days

Sponsors & Collaborators

  • Novan, Inc.

    lead INDUSTRY

Principal Investigators

  • M Joyce Rico, MD · Novan, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-19
Primary Completion
2017-01-31
Completion
2017-02-01

Countries

  • Dominican Republic

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02860052 on ClinicalTrials.gov